

At page 13, line 22, please insert a --®-- after the word "Cryo-Med".

At page 16, line 2, please insert a --®-- after the first "Haemonetics".

At page 16, line 18, please insert a --®-- after the word "Cryo-Med".

IN THE CLAIMS:

Please amend claims 9-11 as follows:

9. (twice amended) A dendritic cell preparation according to claim 8 produced further by contacting the hematopoietic stem or progenitor cells with one or more compounds selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 antibody and CD40 ligand [binding protein].

10. (twice amended) A dendritic cell population produced by the process of :

(a) contacting hematopoietic stem or progenitor cells with flt3-ligand in an amount sufficient to generate a dendritic cell population;

(b) [either (i) exposing the dendritic cells to an antigen-specific peptide or (ii)] transfecting the dendritic cells with a gene encoding an antigen[-specific peptide]; and

(c) allowing the dendritic cells to process and express the antigen.

11. (twice amended) A dendritic cell population according to claim 10 wherein [step (a) of] the process further comprises contacting the hematopoietic stem or progenitor cells with one or more compounds selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 antibody and CD40 ligand [binding protein].

Please add the following new claims:

--15. (new) A dendritic cell population produced by the process of :

(a) contacting hematopoietic stem or progenitor cells with flt3-ligand in an amount sufficient to generate a dendritic cell population;

(b) exposing the dendritic cells to an antigen; and

(c) allowing the dendritic cells to process and express the antigen.--

RECEIVED

MAY 19 2000

--16. (new) A dendritic cell population according to claim 15 wherein the process further comprises contacting the hematopoietic stem or progenitor cells with one or more compounds selected from the group consisting of GM-CSF, IL-4, TNF- α , IL-3, c-kit ligand, fusions of GM-CSF and IL-3, CD40 antibody and CD40 ligand.--

--17. (new) The dendritic cell preparation according to claim 8 containing recombinant human flt3-ligand.--

--18. (new) The dendritic cell preparation according to claim 9 containing recombinant human flt3-ligand.--

--19. (new) The dendritic cell preparation according to claim 10 wherein the flt3-ligand is a recombinant human flt3-ligand.--

--20. (new) The dendritic cell preparation according to claim 11 wherein the flt3-ligand is a recombinant human flt3-ligand.--

--21. (new) The dendritic cell preparation according to claim 15 wherein the flt3-ligand is a recombinant human flt3-ligand.--

--22. (new) The dendritic cell preparation according to claim 16 wherein the flt3-ligand is a recombinant human flt3-ligand.--

--23. (new) The dendritic cell preparation according to claim 18 containing recombinant human GM-CSF.--

--24. (new) The dendritic cell preparation according to claim 20 wherein the compound is a recombinant human GM-CSF.--

--25. (new) The dendritic cell preparation according to claim 22 wherein the compound is a recombinant human GM-CSF.--